Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Income from Continuing Operations (2019 - 2026)

ADC Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 32968000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 32968000.0 for Q1 2026, up 14.6% from a year ago — trailing twelve months through Mar 2026 was 169182000.0 (down 3.0% YoY), and the annual figure for FY2022 was 153522.0, up 99.93%.
  • Income from Continuing Operations reached 32968000.0 in Q1 2026 per ADCT's latest filing, up from 40966000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 16223.0 in Q4 2022 and bottomed at 66268000.0 in Q2 2022.
  • Median Income from Continuing Operations over the past 5 years was 44512000.0 (2023), compared with a mean of 41826515.93.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 97.15% in 2022 before it plummeted 215.51% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 16223.0 in 2022, then plummeted by 279225.65% to 45315000.0 in 2023, then rose by 3.54% to 43709000.0 in 2024, then rose by 6.28% to 40966000.0 in 2025, then grew by 19.52% to 32968000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for ADCT at 32968000.0 in Q1 2026, 40966000.0 in Q3 2025, and 56646000.0 in Q2 2025.